2294-P: Characteristics and Clinical Outcomes of Patients with Chronic Kidney Disease and Type 2 Diabetes Using Finerenone in China: A Real-World Retrospective Cohort Study

Introduction and Objective: Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). This study aimed to describe the characteristics and clinical outcomes in patients with CKD and T2D using finerenone in a real-world setting in China. Methods: A retrospective study was conducted using electronic health records data in Tianjin, China. Adult patients with CKD and T2D who initiated finerenone between 1 JAN 2023 and 31 DEC 2024 were included, with up to 28.8 months of follow-up. Patient characteristics were descriptively summarized. Relative change from baseline in urine albumin-to-creatinine ratio (UACR) was evaluated at 4 months. Hyperkalemia occurrence was assessed. Results: The study included 6,537 patients. Baseline characteristics are provided in Table 1. At baseline, in 2,561 patients with UACR and estimated glomerular filtration rate (eGFR) values, 43.5% and 41.4% were categorized as moderate and high KDIGO risk categories. UACR was reduced by 40.7% (95% confidence interval: 32.2%, 49.1%) at 4 months. The incidence rate of hyperkalemia was 4.1 per 100 person-years. Conclusion: This study provides evidence on characteristics and clinical outcomes of finerenone new users based on real-world data in China. Patients who initiated finerenone experienced a significant reduction in UACR, with a low risk profile for hyperkalemia. Disclosure B. Sun: None. C. Shan: None. Y. Kong: None. Z. Xu: Other - Employee of Bayer Healthcare Company Ltd; Current; Bayer AG. H. Yang: Other - employee for Bayer Healthcare Company LTD.; Current; Bayer AG. N.G. Oberprieler: Employee; Current; Bayer AG. H. Wei: None. L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi. Funding This study was initiated by Bayer Healthcare Company Ltd. and funded by Bayer AG.